Patients with previously treated metastatic, castration-resistant prostate cancer (mCRPC) see no benefit when custirsen is added to the combination of Jevtana (cabazitaxel) and prednisole, according to the results of a Phase 3 clinical trial. The data, presented at the recent European Society for Medical Oncology (ESMO) 2016 Congress, show that patients treated with the custirsen, Jevtana, and prednisone combination have similar survival rates compared to those treated with Jevtana and prednisone alone. "Despite the negative outcome of the trial, the evaluation of custirsen in prostate cancer was conducted on the basis of solid preclinical and clinical evidence supporting anti-tumor activity," principal investigator Karim Fizazi, head of the Department of Cancer Medicine at the Institut Gustave Roussy, in Villejuif, France, said in a press release. Previous data from a Phase 2 trial (NCT00258388) suggested that custirsen could improve the outcomes of mCRPC patients when combined with chemotherapy, and a Phase 3 trial of custirsen in combination with Taxotere (docetaxel) showed promising results in patients with more aggressive cancers. "Given the results observed using a taxane as either first-line or second-line chemotherapy in castration resistant prostate cancer, the hypothesis was that combination with custirsen may decrease taxane resistance and enhance the survival benefit of taxane therapy," said Dr. Cora Sternberg, chief of the Department of Medical Oncology at San Camillo Forlanini Hospital, in Rome, Italy.